Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
The Fate of Gaming: 5 Energizing Advancements Not too far off - 2In these U.S. groups, deaths now exceed births. What’s happening?
- 3Figure out How to Involve a Brain science Certification in Showcasing
- 4Step by step instructions to Choose the Right Internet based Degree Program for Your Future
- 5Surging measles cases are 'fire alarm' warning that other diseases could be next
- Oil magnate’s Venezuela detainment spooks industry
- Picking the Right Home Machines: A Commonsense Aide
- The Fragrant Small Tree Birds & Pollinators Love With Stunning Flowers In Summer
- Nearly 16,000 New York City nurses prepare to strike as contract talks stall
- Kona SUV: Exploring the Future with Hyundai's Visionary Hybrid
- Dirty soda started as a Mormon alternative to booze. Now it's everywhere.
- South African radio presenter among five charged over Russia recruitment plot
- Joshua Made Last-Second Seat Change That Saved His Life
- The ‘Stranger Things’ finale, explained: What happens to Vecna? And why was a key character’s fate left unknown?
